Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Follow-Up Questions
What is Minerva Neurosciences Inc (NERV)'s P/E Ratio?
The P/E ratio of Minerva Neurosciences Inc is 10.393
Who is the CEO of Minerva Neurosciences Inc?
Dr. Remy Luthringer is the Executive Chairman of the Board of Directors of Minerva Neurosciences Inc, joining the firm since 2014.
What is the price performance of NERV stock?
The current price of NERV is $2.02, it has decreased 1.94% in the last trading day.
What are the primary business themes or industries for Minerva Neurosciences Inc?
Minerva Neurosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Minerva Neurosciences Inc market cap?
Minerva Neurosciences Inc's current market cap is $14.1M
Is Minerva Neurosciences Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Minerva Neurosciences Inc, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell
